Treatment with C5i
| Reason for commencing C5i . | Number (%) . |
|---|---|
| Intravascular hemolysis | 452 (88.8%) |
| Other PNH complication | 13 (2.6%) |
| Allogeneic bone marrow transplant | 13 (2.6%) |
| Pregnancy | 19 (3.7%) |
| Exceptional case | 12 (2.4%) |
| Treatment on C5i | |
| Median PNH granulocyte clone size at initiation of C5i | 85.5%∗ (range 12%-100%) |
| Median PNH erythrocyte clone size at initiation of C5i | 28.%† (range 0%-100%) |
| Death | 91 (17.9%) |
| Thromboses | 23 (4.5%) |
| Neisseria meningitidis infection | 11 (2.2%) |
| Clonal evolution to MDS or AML | 14 (2.8%) |
| Mean hemoglobin level 12 months after starting C5i‡ | 107.7g/l |
| Mean hemoglobin level 24 months after starting C5i§ | 108.6g/l |
| Requiring transfusions in the most recent 12 months on C5i‡ | 123 (26.7%) |
| Normalization of hemoglobin level at 12 months‡ | 86 (20.4%) |
| Normalization of hemoglobin level at 24 months§ | 76 (20.3%) |
| Discontinuation of C5i because of disease remission | 20 (3.9%) |
| Reason for commencing C5i . | Number (%) . |
|---|---|
| Intravascular hemolysis | 452 (88.8%) |
| Other PNH complication | 13 (2.6%) |
| Allogeneic bone marrow transplant | 13 (2.6%) |
| Pregnancy | 19 (3.7%) |
| Exceptional case | 12 (2.4%) |
| Treatment on C5i | |
| Median PNH granulocyte clone size at initiation of C5i | 85.5%∗ (range 12%-100%) |
| Median PNH erythrocyte clone size at initiation of C5i | 28.%† (range 0%-100%) |
| Death | 91 (17.9%) |
| Thromboses | 23 (4.5%) |
| Neisseria meningitidis infection | 11 (2.2%) |
| Clonal evolution to MDS or AML | 14 (2.8%) |
| Mean hemoglobin level 12 months after starting C5i‡ | 107.7g/l |
| Mean hemoglobin level 24 months after starting C5i§ | 108.6g/l |
| Requiring transfusions in the most recent 12 months on C5i‡ | 123 (26.7%) |
| Normalization of hemoglobin level at 12 months‡ | 86 (20.4%) |
| Normalization of hemoglobin level at 24 months§ | 76 (20.3%) |
| Discontinuation of C5i because of disease remission | 20 (3.9%) |